Future experiments should aim to elucidate the connection between TIGIT and other immune checkpoints, particularly those involved in the immune response against cancers which do not express PD-L1, as well as the interplay with HIF-1α and the A2A receptor. The gene discussed is CD274; the disease is cancer.